<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016874</url>
  </required_header>
  <id_info>
    <org_study_id>VION-CLI-015</org_study_id>
    <secondary_id>CDR0000068591</secondary_id>
    <secondary_id>AECM-1200012380</secondary_id>
    <secondary_id>NCI-V01-1658</secondary_id>
    <nct_id>NCT00016874</nct_id>
  </id_info>
  <brief_title>3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer</brief_title>
  <official_title>A Phase I Study Of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) In Combination With Cisplatin And Paclitaxel In Patients With Advanced And Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining 3-AP, cisplatin, and&#xD;
      paclitaxel in treating patients who have advanced or metastatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and tolerability of 3-AP, cisplatin, and paclitaxel in patients&#xD;
           with advanced or metastatic cancer.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of this regimen in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic parameters of this regimen in these patients.&#xD;
&#xD;
        -  Determine the tumor response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive 3-AP IV continuously over 96 hours on days 1-4 and paclitaxel IV over 3&#xD;
      hours followed by cisplatin IV over 1 hour on day 3. Courses repeat every 21 days in the&#xD;
      absence of disease progression or unacceptable toxicity. Patients achieving complete response&#xD;
      (CR) receive 1 additional course of therapy after documented CR. Patients with partial&#xD;
      response or stable disease may receive therapy for up to 6 months.&#xD;
&#xD;
      Cohorts of 1-6 patients receive escalating doses of 3-AP, paclitaxel, and cisplatin until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 25-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed progressive advanced or metastatic cancer&#xD;
&#xD;
               -  Failed 1 or more prior standard therapies for disease OR&#xD;
&#xD;
               -  Unlikely to respond to any currently available therapies&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No active CNS metastases&#xD;
&#xD;
               -  Previously treated CNS metastases allowed if no evidence of new CNS metastases&#xD;
                  and stable for at least 2 months&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL (transfusion allowed)&#xD;
&#xD;
          -  No active bleeding or coagulation disorder (occult blood for gastrointestinal cancer&#xD;
             allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  ALT/AST no greater than 3 times upper limit of normal (ULN) (5 times ULN if liver&#xD;
             metastases present)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 3 times ULN (5 times ULN if liver metastases&#xD;
             present)&#xD;
&#xD;
          -  Albumin at least 3.0 g/dL&#xD;
&#xD;
          -  PT/PTT no greater than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No active heart disease&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No symptomatic coronary artery disease, heart block, or uncontrolled congestive heart&#xD;
             failure&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No moderate to severe compromise in pulmonary function&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No mental deficits and/or psychiatric history that would preclude study&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No pre-existing severe hearing impairment&#xD;
&#xD;
          -  No pre-existing grade 2 or greater neuropathy&#xD;
&#xD;
          -  No prior severe allergic reaction to study drugs&#xD;
&#xD;
          -  No other life-threatening illness&#xD;
&#xD;
          -  No chronic toxic effects from prior chemotherapy greater than grade I&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 18 months after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Concurrent hematopoietic growth factors allowed except if used prophylactically during&#xD;
             first course of study therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  More than 6 months since prior combination cisplatin and paclitaxel&#xD;
&#xD;
          -  Prior cisplatin or paclitaxel as single agents allowed&#xD;
&#xD;
          -  Prior 3-AP allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  Concurrent radiotherapy to a single site of progressive disease allowed if site&#xD;
             requires treatment within the first course of study therapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  More than 3 weeks since any therapy for malignancy and recovered&#xD;
&#xD;
          -  No other concurrent investigational drugs without consent of sponsor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Sznol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein Comprehensive Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Cornell Campus</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>September 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2003</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

